Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 3/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129009 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL18591893 | 0.75 | DGAT1 (0.46) | DGAT1USP30LPLLIPG | |
| SCHEMBL20133098 | 0.74 | DGAT1 (0.48) | DGAT1USP30LPLLIPG | |
| SCHEMBL22086550 | 0.74 | DGAT1 (0.49) | DGAT1USP30LPLLIPG | |
| SCHEMBL30582587 | 0.74 | DGAT1 (0.49) | DGAT1USP30LPLLIPG | |
| SCHEMBL23148377 | 0.72 | DGAT1 (0.47) | DGAT1USP30LPLLIPG | |
| SCHEMBL31368502 | 0.72 | DGAT1 (0.47) | DGAT1USP30LPLLIPG | |
| SCHEMBL20532435 | 0.72 | DGAT1 (0.47) | DGAT1USP30LPLLIPG | |
| SCHEMBL14659740 | 0.72 | DGAT1 (0.47) | DGAT1USP30LPLLIPG | |
| SCHEMBL22712046 | 0.71 | DGAT1 (0.46) | DGAT1USP30LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DGAT1 4519/4885USP30 168/4885LPL 3826/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | DGAT1 4651/4885USP30 108/4885LPL 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.